newsfilter
← Latest News
PR Newswire·

CTI BioPharma Reports Second Quarter 2022 Financial Results

– VONJO® (pacritinib) net product revenue of $12.3 million in the second quarter – – Management to host conference call today at 4:30 p.m. ET – SEATTLE, Aug. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financ